NanoViricides, Inc.

Equities

NNVC

US6300873022

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:00 12/06/2024 am IST			5-day change	1st Jan Change
3.31 ^USD	+9.24%		+36.78%	+224.51%

11/06	Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect	CI
04/06	NanoViricides, Inc. Reports on the Highly Desirable Blood Concentration Profile of its Lead Clinical Stage Broad-Spectrum Antiviral Agent NV-387 Upon Intravenous	CI

Nanoviricides, Inc. Announces Resignation of Mukund Kulkarni as Member of the Board of Directors and Member of Audit, Nominating and Compensation Committees

August 02, 2019 at 02:01 am IST

Effective July 31, 2019, Dr. Mukund Kulkarni resigned as a Member of the Board of Directors of NanoViricides, Inc. as well as a Member of its Audit, Nominating and Compensation Committees. Dr. Kulkarni resigned for personal reasons.

Latest news about NanoViricides, Inc.

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect	11/06	CI
NanoViricides, Inc. Reports on the Highly Desirable Blood Concentration Profile of its Lead Clinical Stage Broad-Spectrum Antiviral Agent NV-387 Upon Intravenous	04/06	CI
NanoViricides, Inc. Intends to Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More	29/05	CI
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	16/05	CI
NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV	14/05	CI
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	08/05	CI
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	06/05	CI
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	30/04	CI
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	15/02	CI
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	01/02	CI
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found	29/01	CI
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2	28/11	CI
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11	CI
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development	14/11	CI
North American Morning Briefing : Geopolitical -2-	18/23/18	DJ
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	14/23/14	CI
North American Morning Briefing : Stock Futures -2-	11/23/11	DJ
Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2	21/23/21	CI
Health Care Down on Cyclical Rotation -- Health Care Roundup	12/23/12	DJ
Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides	11/23/11	CI
Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well	06/23/06	CI
Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun	29/23/29	CI
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	16/23/16	CI
NanoViricides Files $150 Million Mixed Shelf	08/23/08	MT
NanoViricides, Inc. Enters into License Agreement with Karveer Meditech Private Limited	01/23/01	CI

Chart NanoViricides, Inc.

Duration

Period

More charts

Company Profile

NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.

Sector

Biotechnology & Medical Research

Calendar

18/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.31 USD

Average target price

6.5 USD

Spread / Average Target

+96.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NANOVIRICIDES, INC.	+224.51%	3.91Cr
VERTEX PHARMACEUTICALS INCORPORATED	+18.34%	12TCr
REGENERON PHARMACEUTICALS, INC.	+15.06%	11TCr
BIONTECH SE	-6.39%	2.38TCr
ARGENX SE	+1.54%	2.24TCr
GENMAB A/S	-14.13%	1.75TCr
BEIGENE, LTD.	-12.07%	1.66TCr
WUXI APPTEC CO., LTD.	-41.64%	1.64TCr
NEUROCRINE BIOSCIENCES, INC.	+1.05%	1.34TCr
SAREPTA THERAPEUTICS, INC.	+25.87%	1.15TCr

Bio Therapeutic Drugs